EUCTR2021-002254-86-NL招募中1 期
Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis - MOVE-IT
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 320
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Men and women between =18 and =75 years of age
- •-History of idiopathic or diabetic gastroparesis cardinal symptoms for =3 months
- •-Evidence of delayed gastric emptying
- •-Average weekly total symptom score of =2.0
- •- Body Mass Index =16 and <35 kg/m2
- •- Exclusion of any mechanical and/or anatomical obstructions, stenosis, structural diseases, or gastric ulcers by upper gastrointestinal endoscopy/an imaging technique
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 256
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 64
排除标准
- •-Participants without access to an internet-capable terminal and/or without an own e-mail address
- •-History of major gastrointestinal surgery
- •-Intrapyloric botulinum toxin injection within 12 months
- •-Active Gastric stimulator implant
- •-Known secondary causes of gastroparesis
- •-Presence of inflammatory bowel disease, eosinophilic oesophagitis, or reflux oesophagitis, acute gastritis
研究者
相似试验
进行中（未招募）
1 期
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal doseidiopathic or diabetic gastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10021227Term: Idiopathic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002254-86-PLDr. Falk Pharma GmbH320
招募中
2 期
Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesisNL-OMON53662Dr. Falk Pharma GmbH28
进行中（未招募）
1 期
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose.CTIS2023-510195-31-00Dr. Falk Pharma GmbH318
招募中
2 期
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose.2023-510195-31-00Dr. Falk Pharma GmbH202
进行中（未招募）
1 期
Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal doseidiopathic or diabetic gastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1Level: LLTClassification code 10021227Term: Idiopathic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002254-86-DEDr. Falk Pharma GmbH320